Lesson plan
Emestedastat
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome. It is taken orally. The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol. Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical. As of June 2026, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome. Clinical effectiveness for Alzheimer's disease has been mixed. In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms. In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.
Article summary
Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome. It is taken orally. The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol. Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical. As of June 2026, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome. Clinical effectiveness for Alzheimer's disease has been mixed. In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms. In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.
Key claims
- publication date: 2026 — source: Wikipedia, revision 1371059574, retrieved 2026-10-20 · confidence 0.95
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- The record states that the publication date is "2026". What evidence would count against this claim?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
- Wikipedia, “Emestedastat”, revision 1371059574, retrieved 2026-10-20 https://en.wikipedia.org/w/index.php?oldid=1371059574
Key claims and bibliography are generated from the same tracked claims and sources as the article page.